Compare Ally Financial Inc (ALLY) vs Amylx Pharmaceuticals Inc (AMLX) Price & Performance

Ally Financial (ALLY) trades at $43.72, down 0.77% today, with a bearish technical signal despite recent earnings beats. The stock shows attractive valuation metrics with a P/E of 10.29 and P/B of 0.98, trading below analyst consensus target of $54.40. Recent Q2 2026 earnings missed expectations, causing a 2.4% decline, though revenue grew 10% year-over-year. The company maintains strong institutional support with 68% analyst buy ratings.

Outlook remains cautiously optimistic given the discounted valuation and solid fundamentals, though near-term pressure exists from recent earnings miss and insider selling. Key risks include credit quality concerns, interest rate sensitivity, and competitive pressures in auto lending. The 24% upside to consensus target suggests potential reward for patient investors despite technical weakness.

AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.

Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.